


VERELAN

AS EFFECTIVE AS PROCARDIA XL[®] IN REDUCING BP AT THE 24TH HOUR^{1,2}

Reduction in mean DBP measured 24±2 hours after dosing



Results of a 12-week, randomized, double-blind, parallel, comparative study of patients with mild-to-moderate hypertension in 10 study sites nationwide. Patients not controlled on VERELAN 240 mg/day were titrated to 360 mg/day and, if needed, 480 mg/day; patients not controlled on Procardia XL 30 mg/day were titrated to 60 mg/day and, if needed, 90 mg/day.

No significant difference between groups in the number of titrations to goal DBP (<90 mm Hg)

¹Procardia XL is a registered trademark of Pfizer Inc.


Constipation, which can easily be managed in most patients, is the most frequently reported side effect of verapamil.

Please see brief summary of Prescribing Information including CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS on last page.

VERELAN

EXCELLENT TOLERABILITY SIMILAR TO PLACEBO IN A DOUBLE-BLIND STUDY*

*Incidence of side effects commonly associated
with calcium channel blockers*



**Results of a 4-week, double-blind, placebo-controlled study of patients with essential hypertension. VERELAN 120 mg/day (n=28), 180 mg/day (n=28), 240 mg/day (n=26), placebo (n=26).*

No patients discontinued VERELAN therapy due to constipation, headache, dizziness, or edema.

ONCE-A-DAY
VERELAN[®]
Verapamil HCl 120 mg
180 mg
240 mg
PELLET-FILLED CAPSULES

ONCE-A-DAY
VERELAN
 Verapamil HCl 120 mg
 180 mg
 240 mg
 PELLET-FILLED CAPSULES

Verelan
 240 mg
 qd
 Sig: T cap
 daily AM

- BP control equal to Procardia XL at the 24th hour
- Excellent side-effect profile — negligible dropout rate
- The only verapamil with once-daily dosing up to 480 mg/day

References: 1. Levy B, Rosenberg LN, Colasanto DA. A comparison of VERELAN® and Procardia® XL in the treatment of patients with mild to moderate hypertension. American College of Clinical Pharmacology, 21st Annual Meeting, 1992. Abstract. 2. Further analysis of Levy B, et al. (See reference 1.) Data on file. Lederle Laboratories, Pearl River, NY. 3. Carr AA, Bottini PB, Prisant LM, et al. Once-daily verapamil in the treatment of mild-to-moderate hypertension: a double-blind placebo-controlled dose-ranging study. *J Clin Pharmacol*: 1991;31:144-150. 4. Further analysis of Carr AA, et al. (See reference 3.) Data on file. Lederle Laboratories, Pearl River, NY. 5. VERELAN Prescribing Information. 6. Physicians' Desk Reference®, 46th ed. Montvale, NJ: Medical Economics Data; 1992:1181-1183 (Isoptin® SR) 2157-2159 (Calan® SR).

Brief Summary

VERELAN®
Verapamil HCl
Sustained-Release Pellet-Filled Capsules

For complete Prescribing Information, consult package insert.

CLINICAL PHARMACOLOGY

Food does not affect the extent or rate of the absorption of verapamil from the controlled release VERELAN capsule. Atrioventricular block can occur in patients without preexisting condition defects (see **WARNINGS**).

Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil (see **WARNINGS**).

In patients with hepatic insufficiency, metabolism is delayed and elimination half-life prolonged up to 14 to 16 hours (see **PRECAUTIONS**), the volume of distribution is increased, and plasma clearance reduced to about 30% of normal.

CONTRAINDICATIONS

Severe LV dysfunction (see **WARNINGS**), hypotension (systolic pressure <90 mmHg) or cardiogenic shock, sick sinus syndrome (if no pacemaker is present), second- or third-degree AV block (if no pacemaker is present), atrial flutter/fibrillation with an accessory bypass tract (eg, WPW or LGL syndromes), (see **WARNINGS**), hypersensitivity to verapamil.

WARNINGS

Verapamil should be avoided in patients with severe LV dysfunction (eg, ejection fraction <30%) or moderate-to-severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta blocker. Control milder heart failure with optimum digitalization and/or diuretics before VERELAN is used. Verapamil may occasionally produce hypotension. Elevations of liver enzymes have been reported.

Several cases of hepatocellular injury have been demonstrated to be produced by verapamil. Periodic monitoring of liver function in patients on verapamil is prudent. Some patients with paroxysmal and/or chronic atrial flutter/fibrillation and an accessory AV pathway (eg, WPW or LGL syndromes) have developed an increased antegrade conduction across the accessory pathway bypassing the AV node, producing a very rapid ventricular response or ventricular fibrillation after receiving IV verapamil (or digitals). Because of this risk, oral verapamil is contraindicated in such patients. AV block may occur (second- or third-degree, 0.8%). Development of marked first-degree block or progression to second- or third-degree block requires reduction in dosage or, rarely, discontinuation and institution of appropriate therapy. Sinus bradycardia, second-degree AV block, sinus arrest, pulmonary edema and/or severe hypotension were seen in some critically ill patients with hypertrophic cardiomyopathy who were treated with verapamil.

PRECAUTIONS

Verapamil should be given cautiously to patients with impaired hepatic function (in severe dysfunction use about 30% of the normal dose) or impaired renal function, and patients should be monitored for abnormal prolongation of the PR interval or other signs of overdose. Verapamil may decrease neuromuscular transmission in patients with Duchenne's muscular dystrophy and may prolong recovery from the neuromuscular blocking agent vecuronium. It may be necessary to decrease verapamil dosage in patients with attenuated neuromuscular transmission. Combined therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction and/or cardiac contractility; there have been reports of excessive bradycardia and AV block, including complete heart block. The risks of such combined therapy may outweigh the benefits. The combination should be used only with caution and

VERELAN® Verapamil HCl

close monitoring. Decreased metoprolol clearance may occur with combined use. Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, which can result in digitalis toxicity. In patients with hepatic cirrhosis, verapamil may reduce total body clearance and extrarenal clearance of digoxin. The digoxin dose should be reduced when verapamil is given and the patient carefully monitored. Verapamil will usually have an additive effect in patients receiving blood pressure-lowering agents. Disopyramide should not be given within 48 hours before or 24 hours after verapamil administration. Concomitant use of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction, and repolarization. Combined verapamil and quinidine therapy in patients with hypertrophic cardiomyopathy should be avoided, since significant hypotension may result. Verapamil has been given concomitantly with short- and long-acting nitrates without any undesirable drug interactions. Interaction between cimetidine and chronically administered verapamil has not been studied. In healthy volunteers, clearance of verapamil was reduced or unchanged. Concomitant use of lithium and verapamil may result in a lowering of serum lithium levels or increased sensitivity to lithium. Patients receiving both drugs must be monitored carefully.

Verapamil may increase carbamazepine concentrations during combined use. Rifampin may reduce verapamil bioavailability. Phenobarbital may increase verapamil clearance. Verapamil may increase serum levels of cyclosporine. Concomitant use of inhalation anesthetics and calcium antagonists needs careful titration to avoid excessive cardiovascular depression. Verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing); dosage reduction may be required. Adequate animal carcinogenicity studies have not been performed. One study in rats did not suggest a tumorigenic potential, and verapamil was not mutagenic in the Ames test. **Pregnancy Category C:** There are no adequate and well-controlled studies in pregnant women. This drug should be used during pregnancy, labor, and delivery only if clearly needed. Verapamil is excreted in breast milk; therefore, nursing should be discontinued during verapamil use. Safety and efficacy of verapamil in children below the age of 18 years have not been established.

ADVERSE REACTIONS

Reversible (upon discontinuation of verapamil) nonobstructive, paralytic ileus has been infrequently reported in association with the use of verapamil.

In clinical trials with 285 hypertensive patients on VERELAN for more than 1 week, the following adverse reactions were reported: constipation (7.4%); headache (5.3%); dizziness (4.2%); lethargy (3.2%); dyspepsia (2.5%); rash (1.4%); ankle edema (1.4%); sleep disturbance (1.4%); myalgia (1.1%). In clinical trials of other formulations of verapamil HCl (N = 4,854), the following reactions have occurred at rates greater than 1.0%: constipation (7.3%); dizziness (3.3%); nausea (2.7%); hypotension (2.5%); edema (1.9%); headache (2.2%); rash (1.2%); CHF/pulmonary edema (1.8%); fatigue (1.7%); bradycardia (HR <50/min) (1.4%); AV block-total 1°, 2°, 3° (1.2%); 2° and 3° (0.8%); flushing (0.6%); elevated liver enzymes (see **WARNINGS**).

The following reactions, reported in 1.0% or less of patients, occurred under conditions (open trials, marketing experience) where a causal relationship is uncertain. **Cardiovascular:** angina pectoris, atrioventricular dissociation, chest pain, claudication, myocardial infarction, palpitations, purpura (vasculitis), syncope. **Digestive System:** diarrhea, dry mouth, gastrointestinal distress, gingival hyperplasia. **Heme and Lymphatic:** ecchymosis or bruising. **Nervous System:** cerebrovascular accident, confusion, equilibrium disorders, insomnia, muscle cramps, paresthesia, psychotic symptoms, shakiness, somnolence. **Respiratory:** dyspnea. **Skin:** arthralgia and rash, exanthema, hair loss, hyperkeratosis, maculae, sweating, urticaria, Stevens-Johnson syndrome, erythema multiforme. **Special Senses:** blurred vision. **Urogenital:** gynecostasia, impotence, increased urination, spotty menstruation.



Manufactured for
LEDERLE LABORATORIES DIVISION
 American Cyanamid Company
 Pearl River, NY 10965



by **ELAN PHARMACEUTICAL RESEARCH CORP.**
 Gainesville, GA 30501

Rev. 1/92
 20801-92



INFORMATION FOR READERS

THE JOURNAL OF THE AMERICAN BOARD OF FAMILY PRACTICE
2228 Young Drive
Lexington, KY 40505

*Official Publication of
The American Board of Family Practice*

John P. Geyman, M.D., *Editor*
Paul R. Young, M.D., *Executive Editor*
Alfred O. Berg, M.D., *Associate Editor*
Paul Brucker, M.D., *Associate Editor*
G. Gayle Stephens, M.D., *Associate Editor*
Claire Z. Fenwick, *Assistant Editor*
Ann Stockham, *Copy Editor and Assistant
Executive Editor*
Virginia M. Gessner, *Senior Editorial
Assistant*
Debbie Wilson, *Production Assistant*
Mary K. Lowell, *Reference Verification*

PUBLISHING SERVICES

Publishing Division
Massachusetts Medical Society
Robert D. Bovenschulte, *Vice President
for Publishing*
William H. Paige, *Executive Director
for Operations*
Christopher R. Lynch, *Director, Business
Planning and Product Management*
Dolores Fletcher, *Rights and Permissions*

Marketing Group

Advertising Sales
Arthur Wilschek, *Director*
William Healy, *Manager, Midwest Accounts*
Lewis Wetzell, *Manager, Eastern Accounts*
Wayne Wickman, *Manager, Eastern
Accounts*
Christine Miller, *Manager, Recruitment
Advertising*

Circulation and Product Marketing

Laurie Pass, *Director*

Market Research and Analysis

Janet E. Halpern, *Director*

Operations Group

Customer Service and Fulfillment
Elizabeth C. Clancy, *Director*

Electronic Production

Ruth E. Goodman, *Director*
Tommie Richardson, *Composition
Coordinator*
Sioux M. Waks, *Senior Typographer*

Manufacturing and Distribution

Mark Davidson, *Director,
Distribution and Postal Affairs*

Mary Kaye Howe, *Director,
Production Operations*
Mark L. Peal, *Director, Production
Services*
Joseph Cortese, *Director, Printing
Services*

Divisional Support Group
Finance
Richard Simoes, *Controller*

Management Information Services
Larry Altrich, *Director*

COPYRIGHT

Material appearing in the *Journal of the American Board of Family Practice* is covered by copyright. Copying beyond the quantities permitted under "fair use" as defined by U.S. copyright law is allowed provided the stated fee of \$.20 per page is paid through the Copyright Clearance Center, 21 Congress St., Salem, MA 01970. This consent does not extend to other copying, such as copying for advertising or promotional purposes. Single copies for personal or internal use are allowed at no charge. Nonprofit institutions may make copies provided they obtain prior consent from the *Journal of the American Board of Family Practice*, Rights and Permissions Department, 1440 Main Street, Waltham, MA 02154-1649, (617) 893-3800, ext. 1413.

SUBSCRIPTION INFORMATION AND SERVICES

The *Journal of the American Board of Family Practice* is supplied free of charge to 50,400 Diplomates and Residents of the American Board of Family Practice. For information please contact:

American Board of Family Practice
2228 Young Drive
Lexington, KY 40505
Tel: (606) 269-5626
FAX: (606) 266-9699

For all other subscribers please contact:

**The Journal of the American Board of
Family Practice**
Subscription Department
1440 Main Street
Waltham, MA 02154-1649
(617) 893-3800, ext. 1199
Telex: 5106017779 NEJM BOS
FAX: (617) 893-0413

For international subscription information please contact:

**The Journal of the American Board of
Family Practice**
Saxon Way, Melbourn, ROYSTON
Herts, SG8 6NJ, U.K.
Telephone: 07-6326-2368
Telex: 94020513 NEJM G
FAX: 07-6326-2401

SUBSCRIPTION RATES

	Domestic	International*
Institutions	\$58.00	\$60.00
Physicians	\$35.00	\$45.00
Residents/Students	\$20.00	\$45.00

*Pounds Sterling drawn on U.K. banks accepted and converted at current rate of exchange. U.S. dollars drawn on U.S. banks.

OTHER SUBSCRIPTION INFORMATION

Diplomates should make address changes on the form accompanying this issue and forward to the Diplomate address listed above. All other subscribers should forward changes to the Waltham, Mass., address listed on this page. Changes must be received at least six weeks in advance of intended move. Please send new address, old address, and expected date of change.

ISSUES NOT RECEIVED

Missing issues will be replaced for up to three months from the issue date without charge. Diplomates and other subscribers who fail to notify the Lexington, Ky., or the Waltham, Mass., office of address changes will not be eligible for free replacement issues. Claims beyond the three-month limit must be prepaid at the backcopy rates. Claims should be sent to either the Diplomate or regular subscriber address listed on this page.

BACK COPIES

If you wish to purchase back copies (issues published prior to your effective start date) of the *Journal of the American Board of Family Practice*, there is a charge of \$12.50 per issue. Contact the Waltham, Mass., address listed above for information.

REPRINTS

Individual copies of articles are available from the Waltham, Mass., office. If you wish to order bulk reprints (minimum order of 100) please contact the Reprint Department (617) 893-3800, ext. 1279, at the Waltham, Mass., office.

INDEXING AND MICROFORM

The *Journal of the American Board of Family Practice* is indexed in *Index Medicus* and is available in microform from University Microfilms International.

INFORMATION FOR AUTHORS

The *Journal of the American Board of Family Practice* welcomes for editorial review manuscripts that contribute to family practice as a clinical scientific discipline. High priority is given to reports of clinically relevant studies that have practical implications for improved patient care. Manuscripts are considered in relation to the extent to which they represent original work, their significance to the advancement of family medicine, and their interest to the practicing family physician. Some papers that are accepted by the *Journal* will be selected for an accompanying guest editorial or concurrent commentary by other invited authors addressing issues raised by the papers. The *Journal* publishes the following features:

Original Articles. Reports of original research, usually dealing with a clinical, health services, or other clinically relevant study.

Medical Practice. Scholarly articles that relate directly to clinical topics useful in everyday family practice, whether dealing with diagnostic or therapeutic roles of the family physician or reporting studies of what family physicians do in practice.

Clinical Review. In-depth reviews of specific clinical problems, disease entities, or treatment modalities; comprehensive and critical analysis of the literature is required (usual maximum length 5000 words).

Clinical Guidelines and Primary Care. Summaries of major clinical guidelines proposed by various specialties, governmental, or health care organizations, with critical commentary from a primary care perspective.

Special Articles. Articles in other areas that may relate to the role of the family physician, education for family practice, or other subjects important to family practice as a clinical specialty.

Brief Reports. Short reports of pilot studies or case reports with a teaching point of clinical relevance (usual length 1000–1500 words).

Family Practice — World Perspective. Papers reporting developments related to the practice or education of family physicians in various countries around the world (usual length 1200–1800 words).

Reflections in Family Practice. Papers in narrative or essay format that illuminate qualitative aspects of family

practice, including such areas as ethical issues, the physician-patient relationship, or the diverse roles of the family physician.

Editorial. Focused opinion or commentary that bears on an issue relevant to the field. May or may not accompany an original article in the same issue (usual length 1000–1500 words).

Letters to the Editor. Observations, opinion, or comment on topics under discussion in the *Journal*, usually not to exceed 500 words.

Book Reviews. Books for review and book reviews should be sent to Dr. John P. Geyman, Editor, the *Journal of the American Board of Family Practice*, Department of Family Medicine (HQ-30), School of Medicine, University of Washington, Seattle, WA 98195.

The following guidelines are in accordance with the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals." The current (fourth) edition was published in the February 7, 1991, issue of the *New England Journal of Medicine*.

MANUSCRIPT SUBMISSION

Manuscripts containing original material are accepted for consideration with the understanding that neither the article nor any part of its essential substance, tables, or figures has been or will be published or submitted for publication elsewhere before appearing in the *Journal*. This restriction does not apply to abstracts or press reports published in connection with scientific meetings. Copies of any possibly duplicative manuscripts should be submitted to the Editor along with the manuscript that is to be considered by the *Journal*. The *Journal* strongly discourages the submission of more than one article dealing with related aspects of the same study. In almost all cases, a single study is best reported in a single paper.

Submit an original and 3 copies of the complete manuscript, including text pages, legends, tables, references, and glossy prints of figures. Only typed copy, on standard-sized typewriter paper and double-spaced throughout, with margins of at least 2.5 cm, is acceptable. Address all submissions to John P. Geyman, M.D., Editor, the *Journal of the American Board of Family Practice*, Department of Family Medicine (HQ-30), School of Medicine, University of Washington, Seattle, WA 98195. A covering letter should

identify the person (with the address and telephone number) responsible for negotiations concerning the manuscript; the letter should make it clear that the final manuscript has been seen and approved by all authors. If authors acknowledge by name persons who provided important technical, advisory, or reviewer contributions, the corresponding author should sign the following statement: "I have obtained written permission from all persons named in the acknowledgment."

The *Journal* expects authors to take public responsibility for their manuscripts, including conception and design of the work, data analysis, writing, and review of the paper. Authors are expected to stand behind the validity of their data and, if asked by the Editor, to submit the actual data for editorial review with the manuscript.

The *Journal* also expects authors to disclose any commercial associations that might pose a conflict of interest in connection with the submitted article. Consultancies, stock ownership or other equity interests, patent-licensing arrangements, and other kinds of associations that might involve conflict of interest should be disclosed to the Editor in a covering letter at the time of submission. Such information will be held in confidence while the paper is under review and will not influence the editorial decision. If the manuscript is accepted, the Editor will discuss with the authors how best to disclose the relevant information. Questions about this policy should be directed to the Editor.

MANUSCRIPTS

Titles and Authors' Names

With the manuscript, provide a page giving the title of the paper; a running foot of fewer than 40 letter spaces; the name(s) of the author(s), including first name(s) and academic degree(s); the name of the department and institution in which the work was done; and the name and address of the author to whom reprint requests should be addressed. All funding sources supporting the work should be routinely acknowledged on the title page, as should all institutional or corporate affiliations of the authors. Two to four key words should be submitted with the manuscripts to be used for purposes of classification by subject. Use terms from the Medical Subject Headings from *Index Medicus* when possible.

Abstracts

Use another page to provide an abstract of not more than 200 words. This abstract should be factual, not descriptive, with its content appropriate to the type of paper. For original articles reporting results of studies, a four-paragraph format should be used labeled Background, Methods, Results, and Conclusions. These should briefly describe, respectively, the object of the study, the methods used, the major results, and the author(s) conclusions. Abstracts are not necessary for Brief Reports or World Perspective papers.

Abbreviations

Except for units of measurement, abbreviations are discouraged. Consult the *Council of Biology Editors Style Manual* (Fifth edition. Bethesda, MD: Council of Biology Editors, 1983) for lists of standard abbreviations. The first time an abbreviation appears, it should be preceded by the words for which it stands.

Drug Names

Generic names should, in general, be used. If an author so desires, brand names may be inserted in parentheses.

Inclusive Language

Sex bias should be avoided and gender-inclusive language used whenever possible.

References

References must be typed in double spacing and numbered consecutively as they are cited. References first cited in tables or figure legends must be numbered so that they will be in sequence with references cited in the text. The style of references is that of the *Index Medicus*. List all authors when there are 6 or fewer; when there are 7 or more, list the first 6, then "et al." Sample references are as follows:

Standard Journal Article

(List all authors, but if the number exceeds 6, give 6 followed by et al. Note that month and issue number are omitted when a journal has continuous pagination throughout a volume.)

Morrow JD, Margolies GR, Rowland J, Roberts LJ 2nd. Evidence that histamine is the causative toxin of scombroid-fish poisoning. *N Engl J Med* 1991; 324:716-20.

Organization as Author

Clinical Experience Network (CEN). A large-scale, office-based study evaluates the use of a new class of nonsedating antihistamines. A report

from CEN. *J Am Board Fam Pract* 1990; 3:241-58.

Book

Rakel RE. Textbook of family practice. 4th ed. Philadelphia: WB Saunders, 1990.

Chapter in Book

Haynes RC Jr. Agents affecting calcification: calcium, parathyroid hormone, calcitonin, vitamin D, and other compounds. In: Gilman AG, Rall TW, Nies AS, Taylor P, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1990.

Government Agency

Schwartz JL. Review and evaluation of smoking cessation methods: the United States and Canada, 1978-1985. Bethesda, MD: Department of Health and Human Services, 1987. (NIH publication no. 87-2940.)

Personal Communications

Numbered references to personal communications, unpublished data, and manuscripts either "in preparation" or "submitted for publication" are unacceptable (see "Permissions"). If essential, such material may be incorporated in the appropriate place in the text.

Tables

Type tables in double spacing on separate sheets, and provide a title for each. For footnotes, use the following symbols, in this sequence: *, †, ‡, §, ||, ¶, **, ††, etc. Excessive tabular data are discouraged. If an article is accepted, the *Journal* will arrange to deposit extensive tables of important data with the National Auxiliary Publications Service (NAPS); we will pay for the deposit and add an appropriate footnote to the text. This service makes microfiche or photocopies of tables available at moderate charges to those who request them.

Illustrations

Figures should be professionally designed. Glossy, black-and-white photographs are requested. Symbols, lettering, and numbering should be clear, and these elements should be large enough to remain legible after the figure has been reduced to fit the width of a single column.

The back of each figure should include the sequence number, the name of the author, and the proper orientation (e.g., "top"). Do not mount the figure on cardboard. Photomicro-

graphs should be cropped to a width of 8 cm, and electron photomicrographs should have internal scale markers.

If photographs of patients are used, either the subjects should not be identifiable or their pictures must be accompanied by written permission to use the figure. Permissions forms are available from the Editor.

Legends for illustrations should be type-written (double-spaced) on a separate sheet and should not appear on the illustrations.

Color illustrations are used from time to time. Send both transparencies and prints for this purpose.

Permissions

Every effort (short of changing the patient data) should be made by the authors to protect the anonymity of patients (and relatives) in any published work. If identification is unavoidable, informed consent should be obtained and attached with the submitted letter; in the case of minors or incompetent patients, consent should be obtained from relatives or guardians.

Materials taken from other sources must be accompanied by a written statement from both author and publisher giving permission to the *Journal* for reproduction. Obtain permission in writing from at least one author of papers still in press, of unpublished data, and of personal communications.

REVIEW AND ACTION

Manuscripts are examined by the editorial staff and are usually sent to outside reviewers. Authors will remain anonymous to outside reviewers and vice versa. External statistical review will be accomplished where appropriate. Every effort will be made to complete the review process as expeditiously as possible.

Copyright Transfer Forms

Transfer of copyright to the *Journal* is requested upon acceptance of the material for publication. Copyright transfer is required of all materials to be published in the *Journal*, including Letters to the Editor and Book Reviews.

Reprints

Authors will receive reprint information and rates when they are sent their galley proofs. Reprints ordered at that time will be shipped about 3 weeks after the publication date.

Hate to Wait?



Don't get aggravated.
Get Updated.

Use your waiting time to read *Journal Watch*, the newsletter that monitors over 20 top journals. It digests the most significant advances so you're briefed on them in just minutes.

You can take *Journal Watch* anywhere. Read it on the go and make profitable use of otherwise-wasted time.

Written by doctors for doctors, this 8-page newsletter published twice monthly brings you news of clinical advances while it's still fresh.

Order your introductory subscription today.

Try *JOURNAL WATCH* Today — Satisfaction Guaranteed

Credit card orders, call toll-free 1-800-843-6356 • FAX orders, 617-893-0413 or mail coupon.

Yes, send me 24 issues of *Journal Watch*, mailed first class for just \$79. If not satisfied, I may cancel anytime for a full refund on all unmailed issues.

Check to *Journal Watch* enclosed

Bill me

Charge my

AmEx

VISA

MasterCard

NAME _____

ADDRESS _____

CITY _____

STATE _____ ZIP _____

CREDIT CARD NO. _____ CARD EXP. DATE _____

SIGNATURE _____

Mail to: *Journal Watch*, P.O. Box 9085, Waltham, MA 02254-9085. ISSN: 0896-7210.
Allow 4-6 weeks for delivery.